openPR Logo
Press release

IoMT (Internet of Medical Things) to drive the Fibromyalgia Antidepressants Market

02-04-2022 01:24 PM CET | Health & Medicine

Press release from: Persistence Market Research

IoMT (Internet of Medical Things) to drive the Fibromyalgia

The Fibromyalgia Antidepressants Market is expected to grow on an irrevocable note in the upcoming period. The medical landscape is witnessing an influx of at-home diagnostic kits. This trend of on-demand products is likely to take the healthcare vertical by storm in the upcoming period. It has been observed that home kits aid in educating patients and bringing them to the medical visits better prepared, thereby curtailing the time taken for diagnosis. The status quo would help in keeping the healthcare vertical’s cash registers ringing going forward as well.
As per Persistence Market Research’s latest industry analysis, the global fibromyalgia antidepressants market was valued at US$ 440.8 Mn in 2020, and is expected to exhibit a healthy CAGR of 8.1% over the forecast period (2021-2031)

Rising prevalence of fibromyalgia caused due chronic back pain, previously associated spinal injury, trauma, osteoarthritis, road accidents, and musculoskeletal disorders are expected to drive demand for better treatment along with effective medications for fibromyalgia. Thus, demand for improved treatment with fibromyalgia antidepressants is expected to provide a positive impetus to market growth.

Treatment cost with branded drugs is significantly higher, and it is expected to remain high when compared with generic drugs or other off-label drugs. These higher costs will drive demand for generic drugs. The generic versions of these drugs are likely to see high demand in low-income economies or in economies where these products are limited or not available.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32898

Consolidation activities, mergers, and acquisitions have emerged as a key growth strategy among industry leaders. This trend is quite evident in key markets for fibromyalgia antidepressants.

For instance, the recent acquisition of Allergan plc by AbbVie Inc. in May 2020. This acquisition enabled AbbVie to strengthen its presence across key therapy areas, including immunology, hematologic oncology, and neuroscience.
Similarly, in June 2019, Eli Lily received FDA approval for its migraine drug Emgality, for its use in the treatment in management of cluster headaches.

Get a Customized Scope to Match Your Need Ask an Expert- sales@persistencemarketresearch.com

Company Profiles:

Pfizer, Inc.
Eli Lilly and Company.
AbbVie, Inc
TONIX Pharmaceuticals Holdings Corp
Virios Therapeutics, Inc.
Aptinyx Inc.

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/32898

Key Takeaways from Market Study

In terms of drug class, duloxetine HCL drug holds around 57.8% market value share. Growth is primarily attributed as duloxetine HCL mainly used to treat patients with diabetes and long-term chronic pain.
Based on distribution channel, hospitals pharmacies are leading with over 46% market share, as more patients are consulted at hospitals for fibromyalgia.
By region, North America is set dominate the global market with a value share of around 45.8% in 2021. Europe is slated to be the second-largest leading regional market with a value share of around 20.5% in 2021.
“Rising number of cases of fibromyalgia and better availability of fibromyalgia antidepressant medication are expected to drive market growth over the coming years,” says an analyst of Persistence Market Research.

Market Competition

New product launches and approvals, agreements, collaborations, and partnerships have emerged as key growth strategies adopted by industry players. By focusing on these strategies, key stakeholders are expanding their geographic footprints and strengthening their existing product portfolios.

In January 2021, Eli Lilly acquired pharmaceutical rights from Aashi Kahei Pharma of its experimental drug in early-stage testing for managing chronic pain.
In October 2020, Eli Lily entered into a collaboration agreement with Daichi Sankyo in Japan for the commercialization of Galcanezumab, an anti-CGRP antibody, which has potential use in the treatment of migrane.
In July 2019, FSD BioSciences, Inc. acquired a U.S.-based company Prismic Pharmaceuticals, which is engaged in developing novel therapies for fibromyalgia treatment.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/32898

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the fibromyalgia anti-depressants market in its latest study, presenting historical demand assessment of 2016 – 2020 and projections for 2021 – 2031.

The research study is based on the drug class (venlafaxine, duloxetine HCL, milnacipran HCL, and others), distribution channel (hospital pharmacies, retail pharmacies, drug stores, online sales), and seven key regions of the world.

Complete Report Details@ https://www.persistencemarketresearch.com/market-research/fibromyalgia-antidepressants-market.asp

Read More Trending "PMR Exclusive Article"-

Immune Repertoire Sequencing Market@ https://www.persistencemarketresearch.com/market-research/immune-repertoire-sequencing-market.asp

Life Science Market@ https://www.persistencemarketresearch.com/market-research/life-science-market.asp

Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com

About us-
Business intelligence is the foundation of every business model employed by Persistence Market Research. Multi-dimensional sources are being put to work, which include big data, customer experience analytics, and real-time data collection. Thus, working on “micros” by Persistence Market Research helps companies overcome their “macro” business challenges.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release IoMT (Internet of Medical Things) to drive the Fibromyalgia Antidepressants Market here

News-ID: 2545474 • Views:

More Releases from Persistence Market Research

Hydrolyzed Vegetable Protein Market Boom Rising from $3.3 Bn in 2025 to $5.3 Bn - Persistence Market Research
Hydrolyzed Vegetable Protein Market Boom Rising from $3.3 Bn in 2025 to $5.3 Bn …
The hydrolyzed vegetable protein (HVP) market is a key contributor to the food and beverage industry, enhancing flavor profiles and nutritional value in processed foods, nutraceuticals, personal care products, and animal feed. HVP, derived from plant-based sources such as soy, corn, and peas, is widely used as a natural flavor enhancer and protein fortification agent. Request a Sample: https://www.persistencemarketresearch.com/samples/10975 According to the latest study by Persistence Market Research, the global market
High Purity Alumina Market to Reach US$ 18.2 Bn by 2032, Driven by Rising Demand for Energy-Efficient Lighting
High Purity Alumina Market to Reach US$ 18.2 Bn by 2032, Driven by Rising Demand …
The global High Purity Alumina (HPA) market is entering a phase of rapid expansion as industries increasingly adopt advanced materials to meet the needs of modern technology. Known for its exceptional properties such as high melting point, superior hardness, chemical stability, and excellent electrical insulation, HPA has become an indispensable material across multiple high-tech industries. According to the latest study by Persistence Market Research, the global HPA market size is estimated
Conductive Carbon Black Market to Reach US$ 541.1 Million by 2025, Driven by Rising Demand from Application Industries
Conductive Carbon Black Market to Reach US$ 541.1 Million by 2025, Driven by Ris …
The global conductive carbon black market is witnessing a significant transformation as industries increasingly focus on materials that enhance conductivity, durability, and performance across a wide range of applications. According to the latest study by Persistence Market Research, the market is expected to achieve a valuation of US$ 541.1 million by 2025, expanding at a robust compound annual growth rate (CAGR) of 7.7% throughout the forecast period from 2025 to
Transparent Barrier Packaging Films Market to Reach US$34.8 Bn by 2031, Driven by Rising Demand for Sustainable Food Packaging
Transparent Barrier Packaging Films Market to Reach US$34.8 Bn by 2031, Driven b …
The global transparent barrier packaging films market is witnessing robust growth, fueled by evolving consumer preferences, the rising importance of product shelf life, and the growing push toward sustainable packaging solutions. According to the latest study by Persistence Market Research, the market is estimated to increase from US$21.9 billion in 2024 to US$34.8 billion by 2031, securing a healthy CAGR of 6.9% during the forecast period. This growth underscores the

All 5 Releases


More Releases for Fibromyalgia

Government Initiatives On Musculoskeletal Health Propel Growth In The Fibromyalg …
The Fibromyalgia Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Projected Growth of the Fibromyalgia Treatment Market? The market for the treatment of fibromyalgia has been expanding consistently in past years. At a compound annual growth rate (CAGR) of 3.9%, it is
SN Clinic's Effective Treatment of Fibromyalgia Symptoms
Image: https://www.globalnewslines.com/uploads/2025/02/1740408683.jpg SN Clinic Logo Fibromyalgia can be a debilitating condition, but SN Clinic offers hope through innovative treatments like MLS Laser Therapy and complementary massage therapies. By addressing chronic pain through a holistic approach, patients can experience significant relief and an improved quality of life. What is Fibromyalgia and What Does Current Data Say? Fibromyalgia is a chronic condition characterized by widespread musculoskeletal pain, fatigue, and tenderness in localized areas. Affecting
Prominent Fibromyalgia Treatment Market Trend for 2025: Market Leaders Focus On …
What Are the Projected Growth and Market Size Trends for the Fibromyalgia Treatment Market? The Fibromyalgia Treatment market is expected to grow from $2.79 billion in 2024 to $2.9 billion in 2025, at a CAGR of 3.9%. This growth is attributed to the increasing prevalence of fibromyalgia, greater awareness about the condition, government initiatives, and rising disposable incomes. The fibromyalgia treatment market is projected to see steady growth, reaching $3.45 billion by
Advancements in Fibromyalgia Treatments Driving Market Expansion
The fibromyalgia treatment market is experiencing a steady upward trajectory, with significant growth expected over the next decade. Estimated at USD 2.77 billion in 2023, the market is projected to reach approximately USD 4.13 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.3% from 2024 to 2032. This expansion is driven by several key factors, including advances in treatment options, increasing demand for effective therapies, and
Fibromyalgia - Drug Pipeline Landscape, 2022
Fibromyalgia is a is a common chronic syndrome characterized by widespread musculoskeletal pain, fatigue, sleep, memory and cognitive issues. Researchers reported that repeated nerve stimulation causes the brain and spinal cord of people with fibromyalgia to change. The conditions conditions that may bring on symptoms, such as: stressors, viral infections or other illnesses like arthritis, anxiety, depression, other mood disorders, PTSD. To know more about Fibromyalgia - Drug Pipeline, visit - https://www.globalinsightservices.com/reports/fibromyalgia-drug-pipeline-landscape-2022/ Fibromyalgia
Fibromyalgia Treatment Market 2022 | Increased Morbidity of Fibromyalgia Along w …
According to Precision Business Insights (PBI), the latest report, the Fibromyalgia Treatment market is expected to be valued at USD 3,017.9 million in 2022, growing at an 3.8% CAGR from 2022 to 2028. Fibromyalgia treatment market analysis projects that the increased prevalence of fibromyalgia and its related complication compelled the introduction of targeted & precise treatment methods for fibromyalgia. Also, the increase in awareness about fibromyalgia will give the required